Asia Pac Allergy.  2015 Jan;5(1):40-46. 10.5415/apallergy.2015.5.1.40.

Tolerance to etoricoxib in children with nonsteroidal anti-inflammatory drug hypersensitivity

• Loh W
• Lim HH
• Rao R
• Goh A
• Ong LX
• Chiang WC

• KMID: 2397066
• DOI: http://doi.org/10.5415/apallergy.2015.5.1.40

Abstract

BACKGROUND
Cyclooxygenase-2 (COX-2) inhibitors have been found to be safe alternatives in adults with cross-intolerant hypersensitivity to nonsteroidal anti-inflammatory drugs (NSAIDs). However they are usually not prescribed in children and there is little information about their tolerance in the pediatric age group.
OBJECTIVE
This study aims to evaluate the tolerance to etoricoxib in children with hypersensitivity to multiple antipyretics.
METHODS
A retrospective case series of children diagnosed with hypersensitivity reactions to NSAIDs and/or paracetamol who underwent a drug provocation test (DPT) with etoricoxib. Information on atopy, family history of allergic diseases, and medication usage was collected. Outcomes of the DPTs and tolerance to etoricoxib were also evaluated.
RESULTS
A total of 24 children, mean age 13.5 years, had a diagnosis of cross-intolerant hypersensitivity to NSAIDs and/or paracetamol. All except one patient successfully tolerated an oral challenge with etoricoxib. Of those who passed the DPT, the majority continued to use etoricoxib with no problems. It was found to be moderately effective in reducing fever and pain.
CONCLUSION
Etoricoxib can be used as a safe alternative in older children with hypersensitivity to multiple antipyretics.

Keyword

Child; Cyclooxygenase-2; Hypersensitivity; Anti-inflammatory agents, Non-steroidal; Acetaminophen

MeSH Terms

Acetaminophen
Adult
Anti-Inflammatory Agents, Non-Steroidal
Antipyretics
Child*
Cyclooxygenase 2
Diagnosis
Drug Hypersensitivity*
Fever
Humans
Hypersensitivity
Retrospective Studies
Acetaminophen
Anti-Inflammatory Agents, Non-Steroidal
Antipyretics
Cyclooxygenase 2

Reference

1. Roberts LJ, Morrow JD. Analgesic-antipyretic and antiinflammatory agents and drugs employed in the treatment of gout. In : Hardman JG, Limbird LL, Goodman Gilman A, editors. The pharmacological basis of therapeutics. 10th ed. New York: McGraw-Hill;2001. p. 687–731.

2. Szczeklik A, Nizankowska E, Sanak M. Hypersensitivity to aspirin and non-steroidal antiinflammtory drugs. In : Adkinson NF, Bochner BS, Busse WW, Holgate S, Lemanske RF, Simons FE, editors. Middelton's allergy, principles and practice. 7th ed. Philadelphia: Mosby;2009. p. 1227–1243.

3. Settipane RA, Constantine HP, Settipane GA. Aspirin intolerance and recurrent urticaria in normal adults and children. Epidemiology and review. Allergy. 1980; 35:149–154.

4. Jenkins C, Costello J, Hodge L. Systematic review of prevalence of aspirin induced asthma and its implications for clinical practice. BMJ. 2004; 328:434.

5. Tan VA, Gerez IF, Van Bever HP. Prevalence of drug allergy in Singaporean children. Singapore Med J. 2009; 50:1158–1161.

6. Stevenson DD, Sanchez-Borges M, Szczeklik A. Classification of allergic and pseudoallergic reactions to drugs that inhibit cyclooxygenase enzymes. Ann Allergy Asthma Immunol. 2001; 87:177–180.

7. Dona I, Blanca-Lopez N, Torres MJ, Garcia-Campos J, Garcia-Nunez I, Gomez F, Salas M, Rondon C, Canto MG, Blanca M. Drug hypersensitivity reactions: response patterns, drug involved, and temporal variations in a large series of patients. J Investig Allergol Clin Immunol. 2012; 22:363–371.

8. Kidon MI, Kang LW, Chin CW, Hoon LS, Hugo VB. Nonsteroidal anti-inflammatory drug hypersensitivity in preschool children. Allergy Asthma Clin Immunol. 2007; 3:114–122.

9. Zambonino MA, Torres MJ, Munoz C, Requena G, Mayorga C, Posadas T, Urda A, Blanca M, Corzo JL. Drug provocation tests in the diagnosis of hypersensitivity reactions to non-steroidal anti-inflammatory drugs in children. Pediatr Allergy Immunol. 2013; 24:151–159.

10. Boussetta K, Ponvert C, Karila C, Bourgeois ML, Blic J, Scheinmann P. Hypersensitivity reactions to paracetamol in children: a study of 25 cases. Allergy. 2005; 60:1174–1177.

11. Pastorello EA, Zara C, Riario-Sforza GG, Pravettoni V, Incorvaia C. Atopy and intolerance of antimicrobial drugs increase the risk of reactions to acetaminophen and nimesulide in patients allergic to nonsteroidal anti-inflammatory drugs. Allergy. 1998; 53:880–884.

12. Kidon MI, Liew WK, Chiang WC, Lim SH, Goh A, Tang JP, Chay OM. Hypersensitivity to paracetamol in Asian children with early onset of nonsteroidal anti-inflammatory drug allergy. Int Arch Allergy Immunol. 2007; 144:51–56.

13. Woessner KM, Simon RA, Stevenson DD. The safety of celecoxib in patients with aspirin-sensitive asthma. Arthritis Rheum. 2002; 46:2201–2206.

14. Martin-Garcia C, Hinojosa M, Berges P, Camacho E, Garcia-Rodriguez R, Alfaya T, Iscar A. Safety of a cyclooxygenase-2 inhibitor in patients with aspirin-sensitive asthma. Chest. 2002; 121:1812–1817.

15. Riendeau D, Percival MD, Brideau C, Charleson S, Dube D, Ethier D, Falgueyret JP, Friesen RW, Gordon R, Greig G, Guay J, Mancini J, Ouellet M, Wong E, Xu L, Boyce S, Visco D, Girard Y, Prasit P, Zamboni R, Rodger IW, Gresser M, Ford-Hutchinson AW, Young RN, Chan CC. Etoricoxib (MK-0663): preclinical profile and comparison with other agents that selectively inhibit cyclooxygenase-2. J Pharmacol Exp Ther. 2001; 296:558–566.

16. Tacconelli S, Capone ML, Sciulli MG, Ricciotti E, Patrignani P. The biochemical selectivity of novel COX-2 inhibitors in whole blood assays of COX-isozyme activity. Curr Med Res Opin. 2002; 18:503–511.

17. Tsoukas C, Eyster ME, Shingo S, Mukhopadhyay S, Giallella KM, Curtis SP, Reicin AS, Melian A. Evaluation of the efficacy and safety of etoricoxib in the treatment of hemophilic arthropathy. Blood. 2006; 107:1785–1790.

18. Sanchez-Borges M, Caballero-Fonseca F, Capriles-Hulett A. Safety of etoricoxib, a new cyclooxygenase 2 inhibitor, in patients with nonsteroidal anti-inflammatory drug-induced urticaria and angioedema. Ann Allergy Asthma Immunol. 2005; 95:154–158.

19. Corzo JL, Zambonino MA, Munoz C, Mayorga C, Requena G, Urda A, Gallego C, Blanca M, Torres MJ. Tolerance to COX-2 inhibitors in children with hypersensitivity to nonsteroidal anti-inflammatory drugs. Br J Dermatol. 2014; 170:725–729.

20. Kidon MI, Kang LW, Chin CW, Hoon LS, See Y, Goh A, Lin JT, Chay OM. Early presentation with angioedema and urticaria in cross-reactive hypersensitivity to nonsteroidal antiinflammatory drugs among young, Asian, atopic children. Pediatrics. 2005; 116:e675–e680.

21. Weberschock TB, Muller SM, Boehncke S, Boehncke WH. Tolerance to coxibs in patients with intolerance to non-steroidal anti-inflammatory drugs (NSAIDs): a systematic structured review of the literature. Arch Dermatol Res. 2007; 299:169–175.

22. Dona I, Blanca-Lopez N, Jagemann LR, Torres MJ, Rondon C, Campo P, Gomez AI, Fernandez J, Laguna JJ, Rosado A, Blanca M, Canto G. Response to a selective COX-2 inhibitor in patients with urticaria/angioedema induced by nonsteroidal anti-inflammatory drugs. Allergy. 2011; 66:1428–1433.

23. Asero R, Quaratino D. Cutaneous hypersensitivity to multiple NSAIDs: never take tolerance to selective COX-2 inhibitors (COXIBs) for granted. Eur Ann Allergy Clin Immunol. 2013; 45:3–6.

24. Llanora GV, Loo EX, Gerez IF, Cheng YK, Shek LP. Etoricoxib: a safe alternative for NSAID intolerance in Asian patients. Asian Pac J Allergy Immunol. 2013; 31:330–333.

25. Sanchez-Borges M, Capriles-Hulett A. Atopy is a risk factor for nonsteroidal anti-inflammatory drug sensitivity. Ann Allergy Asthma Immunol. 2000; 84:101–106.

26. Rachelefsky GS, Coulson A, Siegel SC, Stiehm ER. Aspirin intolerance in chronic childhood asthma: detected by oral challenge. Pediatrics. 1975; 56:443–448.

27. Chiang WC, Chen YM, Tan HK, Balakrishnan A, Liew WK, Lim HH, Goh SH, Loh WY, Wong P, Teoh OH, Goh A, Chay OM. Allergic rhinitis and non-allergic rhinitis in children in the tropics: prevalence and risk associations. Pediatr Pulmonol. 2012; 47:1026–1033.

28. Wang XS, Tan TN, Shek LP, Chng SY, Hia CP, Ong NB, Ma S, Lee BW, Goh DY. The prevalence of asthma and allergies in Singapore; data from two ISAAC surveys seven years apart. Arch Dis Child. 2004; 89:423–426.

29. Yilmaz O, Ertoy Karagol IH, Bakirtas A, Topal E, Celik GE, Demirsoy MS, Turktas I. Challenge-proven nonsteroidal anti-inflammatory drug hypersensitivity in children. Allergy. 2013; 68:1555–1561.

30. Matucci A, Parronchi P, Vultaggio A, Rossi O, Brugnolo F, Maggi E, Romagnani S. Partial safety of the new COX-2 inhibitor rofecoxib in NSAIDs high sensitive patients. Allergy. 2004; 59:1133–1134.